drugset / Trial / NCT00145158

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

NCT00145158

Phase 1/2 Terminated 23 enrolled Ludwig Institute for Cancer Research
Non-randomizedSequentialOpen-labelTreatment

Summary

The purposes of this study are to describe the immune response to individual peptides after immunization with a combination of 8 peptides and CpG 7909 or Montanide ISA51; to determine the safety of the vaccines and; to document the tumor response in patients receiving the vaccines.

Timeline

Start
2005-01
Primary completion
2007-11-30
Completion
2009-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MAGE-1.A2 Peptide 300 ug
Subject MAGE-10.A2 Peptide 150 ug
Subject MAGE-3.A2 Peptide 300 ug
Subject MAGE-4.A2 Peptide 300 ug
Subject MAGE-C2.A2 Peptide 300 ug
Subject NA17.A2 Peptide 300 ug Intramuscular
Subject NY-ESO-1.A2 Unknown 300 ug Subcutaneous
Subject Tyrosinase.A2 Peptide 300 ug Subcutaneous
Subject agatolimod Oligonucleotide (other) 4 mg
Subject incomplete Freund's adjuvant Other / unclassified 0.5 ml

Indications